223 related articles for article (PubMed ID: 32397113)
21. The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study.
Santini V; Almeida A; Giagounidis A; Platzbecker U; Buckstein R; Beach CL; Guo S; Altincatal A; Wu C; Fenaux P
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):136-144.e7. PubMed ID: 29429612
[TBL] [Abstract][Full Text] [Related]
22. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.
Sekeres MA; Maciejewski JP; Giagounidis AA; Wride K; Knight R; Raza A; List AF
J Clin Oncol; 2008 Dec; 26(36):5943-9. PubMed ID: 19018091
[TBL] [Abstract][Full Text] [Related]
23. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
Venugopal S; Mascarenhas J; Steensma DP
Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
[TBL] [Abstract][Full Text] [Related]
24. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
[TBL] [Abstract][Full Text] [Related]
25. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
Fang J; Liu X; Bolanos L; Barker B; Rigolino C; Cortelezzi A; Oliva EN; Cuzzola M; Grimes HL; Fontanillo C; Komurov K; MacBeth K; Starczynowski DT
Nat Med; 2016 Jul; 22(7):727-34. PubMed ID: 27294874
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
Giagounidis AA; Haase S; Heinsch M; Göhring G; Schlegelberger B; Aul C
Ann Hematol; 2007 Feb; 86(2):133-7. PubMed ID: 17111142
[TBL] [Abstract][Full Text] [Related]
27. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
Caceres G; McGraw K; Yip BH; Pellagatti A; Johnson J; Zhang L; Liu K; Zhang LM; Fulp WJ; Lee JH; Al Ali NH; Basiorka A; Smith LJ; Daugherty FJ; Littleton N; Wells RA; Sokol L; Wei S; Komrokji RS; Boultwood J; List AF
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16127-32. PubMed ID: 24043769
[TBL] [Abstract][Full Text] [Related]
28. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
29. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
30. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
31. PP2A: The Achilles Heal in MDS with 5q Deletion.
Sallman DA; Wei S; List A
Front Oncol; 2014; 4():264. PubMed ID: 25295231
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
[TBL] [Abstract][Full Text] [Related]
33. Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
Scharenberg C; Giai V; Pellagatti A; Saft L; Dimitriou M; Jansson M; Jädersten M; Grandien A; Douagi I; Neuberg DS; LeBlanc K; Boultwood J; Karimi M; Jacobsen SE; Woll PS; Hellström-Lindberg E
Haematologica; 2017 Mar; 102(3):498-508. PubMed ID: 27884971
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic Syndrome with concomitant t(5;21)(q15;q22) and del(5)(q13q33): case report and review of literature.
Kasi Loknath Kumar A; Weckbaugh B; Sirridge C; Woodroof J; Persons D; Kambhampati S
Stem Cell Investig; 2016; 3():3. PubMed ID: 27358895
[TBL] [Abstract][Full Text] [Related]
35. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.
Venner CP; Woltosz JW; Nevill TJ; Deeg HJ; Caceres G; Platzbecker U; Scott BL; Sokol L; Sung S; List AF; Karsan A
Haematologica; 2013 Mar; 98(3):409-13. PubMed ID: 22929976
[TBL] [Abstract][Full Text] [Related]
36. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.
van de Loosdrecht AA; Cremers EMP; Alhan C; Duetz C; In 't Hout FEM; Visser-Wisselaar HA; Chitu DA; Verbrugge A; Cunha SM; Ossenkoppele GJ; Janssen JJWM; Klein SK; Vellenga E; Huls GA; Muus P; Langemeijer SMC; de Greef GE; Te Boekhorst PAW; Raaijmakers MHG; van Marwijk Kooy M; Legdeur MC; Wegman JJ; Deenik W; de Weerdt O; van Maanen-Lamme TM; Jobse P; van Kampen RJW; Beeker A; Wijermans PW; Biemond BJ; Tanis BC; van Esser JWJ; Schaar CG; Noordzij-Nooteboom HS; Jacobs EMG; de Graaf AO; Jongen-Lavrencic M; Stevens-Kroef MJPL; Westers TM; Jansen JH
Leukemia; 2024 Apr; 38(4):840-850. PubMed ID: 38297135
[TBL] [Abstract][Full Text] [Related]
37. Role of lenalidomide in the treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.
Messingerová L; Jonášová A; Barančik M; Poleková L; Šereš M; Gibalová L; Breier A; Sulová Z
Gen Physiol Biophys; 2015 Oct; 34(4):399-406. PubMed ID: 26001289
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide for treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
